atumelnant (CRN04894)

DRUG2 trials

Sponsors

Crinetics Pharmaceuticals Inc.

Conditions

Classic Congenital Adrenal HyperplasiaCongenital Adrenal Hyperplasia

Phase 2

Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

CompletedNCT05907291

Crinetics Pharmaceuticals Inc.Classic Congenital Adrenal Hyperplasia, Congenital Adrenal Hyperplasia

Start: 2023-07-03End: 2025-08-22Updated: 2026-09-10

An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia

RecruitingNCT06712823

Crinetics Pharmaceuticals Inc.Classic Congenital Adrenal Hyperplasia, Congenital Adrenal Hyperplasia

Start: 2025-02-25End: 2029-08-01Target: 200Updated: 2026-06-29

Related Papers

SAT-452 Reductions in Adrenal Volume in Patients With Congenital Adrenal Hyperplasia Receiving Once-Daily Oral Atumelnant (CRN04894): Interim Results From a 12-Week, Phase 2, Open-Label Study

Journal of the Endocrine Society2025-10-011 citations

OR07-06 Once-Daily Oral Atumelnant (CRN04894) Induces Rapid, Substantial, and Sustained Reductions of Androstenedione and 17-Hydroxyprogesterone in Adults With Classical Congenital Adrenal Hyperplasia: Interim Results From a 12-Week, Phase 2, Open-Label Study

Journal of the Endocrine Society2025-10-01

12537 Once Daily Oral Atumelnant (CRN04894) Induces Rapid And Profound Reductions Of Androstenedione And 17-Hydroxyprogesterone In Participants With Classical Congenital Adrenal Hyperplasia: Initial Results From A 12-Week, Phase 2, Open-Label Study

Journal of the Endocrine Society2024-10-017 citations